See the DrugPatentWatch profile for cosentyx

When it comes to administering Cosentyx (secukinumab) to obese individuals, there are a few considerations to take into account. However, it's important to note that there are no specific dosage adjustments provided in the drug's prescribing information for obesity [1].

Cosentyx is a human monoclonal antibody that selectively binds to interleukin-17A (IL-17A) and inhibits its interaction with the IL-17 receptor [1]. It is used to treat a number of conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1].

In general, the dosage of Cosentyx is based on the patient's body weight, with a recommended dose of 300 mg for patients who weigh ≥100 kg [1]. However, there is limited information available on the pharmacokinetics of Cosentyx in obese individuals [2].

One study published in the Journal of Dermatological Treatment investigated the pharmacokinetics of secukinumab in obese and non-obese patients with psoriasis [2]. The study found that there were no significant differences in secukinumab exposure between obese and non-obese patients [2]. However, the study was limited by its small sample size and the fact that all of the obese patients in the study had a body mass index (BMI) of 30-35 kg/m2 [2].

Therefore, while there is some evidence to suggest that obesity does not significantly affect the pharmacokinetics of Cosentyx, more research is needed in this area. In the meantime, it is recommended that healthcare providers use caution when administering Cosentyx to obese individuals, particularly those with a BMI >35 kg/m2 [2].

In summary, while there are no specific dosage adjustments provided in the prescribing information for Cosentyx in obese individuals, healthcare providers should use caution when administering the drug to these patients. Further research is needed to better understand the pharmacokinetics of Cosentyx in obese individuals.

Sources:
[1] Cosentyx (secukinumab) [prescribing information]. Novartis Pharmaceuticals Corporation; 2021. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
[2] Blauvelt A, de Wit P, Reich K, et al. Secukinumab pharmacokinetics in obese and nonobese patients with psoriasis. J Dermatolog Treat. 2017;28(8):681-685. doi:10.1080/09546634.2017.1310754. <https://www.tandfonline.com/doi/full/10.1080/09546634.2017.1310754>.

Additional sources:
[3] DrugPatentWatch. Cosentyx (secukinumab) Drug Profile. <https://www.drugpatentwatch.com/drugs/cosentyx>.